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Abstract
Background: Preeclampsia and HELLP syndrome may have serious consequences for both mother and fetus.
Women who have suffered from preeclampsia or the HELLP syndrome, have an increased risk of developing
preeclampsia in a subsequent pregnancy. However, most women will develop no or only minor complications. In
this study, we intend to determine cost-effectiveness of recurrence risk guided care versus care as usual in
pregnant women with a history of early-onset preeclampsia.
Methods/design: We developed a prediction model to estimate the individual risk of recurrence of early-onset
preeclampsia and the HELLP syndrome. In a before-after study, pregnant women with preeclampsia or HELLP
syndrome in their previous pregnancy receiving care as usual (before introduction of the prediction model) will be
compared with women receiving recurrence risk guided care (after introduction of the prediction model).
Eligible and pregnant women will be recruited at six university hospitals and seven large non-university tertiary
referral hospitals in the Netherlands.
The primary outcome measure is the recurrence of early-onset preeclampsia or HELLP syndrome in women
allocated to the regular monitoring group.
For the economic evaluation, a modelling approach will be used. Costs and effects of recurrence risk guided care
with those of care as usual will be compared by means of a decision model. Two incremental cost-effectiveness
ratios will be calculated: 1) cost per Quality Adjusted Life Year (mother unit of analysis) and 2) cost per live born
child (child unit of analysis).
Discussion: This is, to our knowledge, the first study that evaluates prospectively the efficacy of a multivariable
prediction rule for recurrent hypertensive disease in pregnancy. Results of this study could either be integrated into
the current guideline on Hypertensive Disorders in Pregnancy, or be used to develop a new guideline.
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Background
The disease
Preeclampsia is defined as de novo development of
hypertension (>140/90 mmHg) in combination with
proteinuria after 20 weeks of gestation in pregnant
women [1]. One of the most severe forms of this disease
is called the HELLP syndrome, which is derived from
the acronyms of the symptoms (Hemolysis, Elevated
Liver enzymes and Low Platelets).
Preeclampsia (also termed early-onset preeclampsia)
and HELLP syndrome may be life-threatening for both
mother and child [2]. In the mother, these disorders
predispose to premature cardiovascular disorders such
as chronic hypertension, ischemic heart disease and
stroke later in life [3]. Studies in children, born after
preeclamptic pregnancies and who were relatively small
at birth, have shown an increased risk of stroke in adult
life, an increased risk of coronary heart disease and
metabolic syndrome [4-6]. Preeclampsia and especially
HELLP syndrome are perceived by patients and their
partners as a highly traumatic life event, both during
and after pregnancy [7].
In the United States and Europe, the prevalence of
clinically relevant preeclampsia is approximately 2% of
all pregnancies, with HELLP syndrome complicating
preeclampsia approximately in 10 to 20% of the cases
[3,8]. Maternal mortality rate in the Netherlands due to
hypertensive disease during pregnancy amounts to 4.0
per 100,000 live births in 1993-2002 [9].
Although several risk factors have been identified, it is
difficult to develop effective strategies for the prevention
and treatment of these disorders [3]. Strategies applied
nowadays are diverse and include antenatal surveillance,
modification of lifestyle, dietary interventions and phar-
macological therapy. In the last two decades, clinical
guidelines for the management of preeclampsia and
HELLP syndrome have been adopted in most developed
countries [10-12].
Clinical management of preeclampsia or HELLP syn-
drome depends on the gestational age at onset, severity
of symptoms, laboratory abnormalities, size and condi-
tion of the unborn infant, disease progression and
response to symptomatic treatment.
Mild preeclampsia is usually managed expectantly, as
opposed to the management of severe preeclampsia
which is more pro-active consisting of the administra-
tion or magnesium sulphate, often combined with anti-
hypertensives [13]. When gestational age is less than 34
weeks and both maternal and fetal condition are satis-
factory, it is usually recommended to prolong pregnancy
for at least 48 hours to benefit optimally from the
enhancing effect of corticosteroid administration on
fetal lung maturation. Fetal surveillance is an important
component of the management. Delivery is the only
causal treatment and therefore, the management of
choice from 37 weeks’ gestation onward [14,15].
The health care problem
Although preeclampsia and HELLP syndrome are con-
sidered diseases of the first pregnancy, the risk of devel-
oping recurrent preeclampsia or HELLP syndrome is
increased among parous women with preeclampsia and/
or HELLP syndrome in their previous pregnancy. Sep
et al. [16] conducted a literature search in order to iden-
tify prediction tests for recurrent disease. The recur-
rence rates reported vary from none to 31 percent for
preeclampsia and from 3 percent to 7 percent for
HELLP syndrome. Fortunately, the majority of women
with a history of preeclampsia or HELLP syndrome have
uncomplicated subsequent pregnancies.
To the best of our knowledge there is at this moment
no consensus about the management of pregnant
women with a history of early-onset preeclampsia or
HELLP syndrome.
As a result, follow-up and counselling of these patients
varies per centre, gynaecologist and patient, and is lar-
gely based on the perceived risk by the responsible care
provider of recurrence of the disease in the next preg-
nancy and the level of anxiety of the patient and its
resulting demand for care. Formerly preeclamptic
patients are often subjected to various medical screening
programmes to detect associated disorders, followed by
additional exams by other specialists or the initiation of
some management (postpartum evaluation). During a
next pregnancy, care varies from regular surveillance by
the gynaecologist to intensive surveillance and counsel-
ling in order to identify the onset of adverse pregnancy
course as early as possible.
Motivation and relevance for the study
This lack of uniformity in the treatment of these
patients asks for more standardisation, e.g. by providing
care tailored to the individualised risk assessment.
Current policy may not be efficient. Since only a small
percentage of these women develop early-onset recur-
rent disease in their next pregnancy, clinical manage-
ment in the next pregnancy may benefit from
subdividing these women into subgroups with or with-
out increased risk. The care provided to these women
can then be adjusted to their actual risk profile. Particu-
larly former patients at low risk are expected to benefit
from this type of risk stratification. Recurrence risk
guided care could lead to a substantial reduction of
(health care) costs and an increased quality of care.
We have recently developed a multiple-factor model
for the prediction of recurrent early-onset preeclampsia
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and/or HELLP syndrome during the current pregnancy
in women with a prior pregnancy complicated by pree-
clampsia and/or HELLP syndrome (van Kuijk SMJ, Nij-
dam ME, Janssen KJ, Sep SJ, Peeters LL, Delahaije DHJ,
Spaanderman ME, Bruinse HW, Franx A, van Rijn BB,
Bots ML, Langenveld J, van der Post AM, Smits LJ:
A preconceptional prediction model for recurrent early-
onset preeclampsia and the HELLP syndrome,
unpublished).
The PreCare study (pregnant women with previous
preeclampsia: efficiency of care based on recurrence risk
estimation), was designed to (1) estimate cost-effective-
ness of recurrence risk guided care versus care as usual
for pregnant women with a previous pregnancy being
complicated by preeclampsia or HELLP syndrome and
(2) to validate the prediction model externally on the
basis of the results of a prospective cohort and to
update the prediction model if necessary. To this end,
we will use the prediction model to differentiate the
intensity of monitoring of pregnant women with a his-
tory of early-onset preeclampsia and/or HELLP syn-
drome. Patients are assigned to either the ‘regular
monitoring’ or ‘intensive monitoring’ protocol. We will
compare this strategy, referred to as recurrence risk
guided care, with usual care for these patients in The
Netherlands.
For this purpose, the following research questions
were specified:
1. What are the effects of recurrence risk guided
care versus care as usual for pregnant women with a
previous preeclamptic pregnancy, on maternal and
fetal morbidity and mortality?
2. What are the effects of recurrence risk guided
care versus care as usual on specific and generic
quality of life, anxiety, depression and development
of posttraumatic stress?
3. What are the societal costs associated with the
effects of recurrence risk guided care versus care as
usual?
4. What is the cost-effectiveness of recurrence risk
guided care versus care as usual?
Development of prediction model
Although earlier studies have identified individual pre-
dictive factors for recurrent preeclampsia, a combina-
tion of variables for the prediction of recurrent
preeclampsia has not been explored until recently.
A simple prepregnant prediction rule which includes
several predictive factors was developed by Sep et al.
[17]. Unfortunately, patient data were collected from a
single hospital and the number of included patients was
limited (n = 186).
We developed a prediction model to estimate the indi-
vidual recurrence risk of recurrence of early-onset pree-
clampsia and/or the HELLP syndrome. We used data of
407 women with early-onset preeclampsia and/or the
HELLP syndrome in their first pregnancy, who had
undergone subsequent postpartum screening and who
had a recorded consecutive ongoing pregnancy for
which maternal and neonatal outcomes were available.
Data were collected from four university hospitals
(Maastricht University Medical Centre, University Medi-
cal Centre Utrecht, Academic Medical Centre Amster-
dam and University Medical Centre St. Radboud
Nijmegen), and one tertiary referral hospital (Máxima
Medical Centre Veldhoven).
Predictors of recurrent disease were preselected based
on availability in the five different hospitals, previous lit-
erature and gynaecologists’ expert opinion. Fasting cir-
culating level of glucose measured at postpartum
screening, gestational age at delivery of the first preg-
nancy, prior small-for-gestational-age newborn, chronic
hypertension and maternal BMI before the second preg-
nancy proved to be the predictors within a logistic
regression model (van Kuijk SMJ, Nijdam ME, Janssen
KJ, Sep SJ, Peeters LL, Delahaije DHJ, Spaanderman
ME, Bruinse HW, Franx A, van Rijn BB, Bots ML,
Langenveld J, van der Post AM, Smits LJ: A preconcep-
tional prediction model for recurrent early-onset pree-
clampsia and the HELLP syndrome, unpublished).
Since a model tends to perform best in the derivation
sample, called ‘overfitting’, we used bootstrapping tech-
niques to internally validate the model. A shrinkage fac-
tor was computed to shrink the regression coefficients
in order to get a more conservative risk estimate.
Methods/design
Design
The PreCare study uses a before-after design, in which
outcomes and costs before the introduction of the pre-
diction model (i.e. care as usual) are compared with out-
comes and costs after introduction of the prediction
model (i.e. recurrence risk guided care).
This study consists of two consecutive phases. In the
first phase of the study, 50 women receiving care as
usual will be followed prospectively from their first
pregnancy-related outpatient visit until 3 months post
partum. These 50 women will receive questionnaires in
order to measure quality of life, anxiety, depression,
posttraumatic stress and costs outside the hospital. Ret-
rospective data of an additional group of 200 women
who have been treated with care as usual in the past
will be collected later on. Then the prediction rule will
be introduced. In the second phase, 250 women will
receive either protocolised regular monitoring or proto-
colised intensive monitoring depending on their risk of
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developing early-onset preeclampsia or HELLP syn-
drome during their current pregnancy, as estimated on
the basis of the prediction model. In regular monitoring,
pregnant women are monitored less intensively than in
intensive monitoring. Regular monitoring and intensive
monitoring are described in detail in the ‘Monitoring
protocols’ section. Figure 1 summarises the design.
Participants/eligibility criteria
In phase 1 and 2, pregnant women (aged 18 years and
older) with preeclampsia and/or HELLP syndrome in
their previous pregnancy who have visited the outpatient
clinic until 16+6 weeks of pregnancy are eligible for par-
ticipation in the PreCare study.
Given these general eligibility criteria, two subgroups
are distinguished in recurrence risk guided care
(phase 2).
In women who gave birth after early-onset preeclamp-
sia or HELLP syndrome until 33+6 weeks gestational
age in the previous pregnancy, the prediction model is
applied in order to allocate the participants to one of
the two monitoring protocols. The data which are
required as input parameters for the prediction model
should be available. These variables mostly come from
the postpartum evaluation.
Women who gave birth between 34 and 36+6 weeks
gestational age in the previous pregnancy face a rela-
tively small risk of developing recurrent preeclampsia or
HELLP syndrome, compared to women who gave birth
before 34 weeks. Therefore, they all are allocated to the
regular monitoring subgroup [18].
Women suffering from severe co-morbidity, such as
diabetes mellitus, SLE, renal disease, cardiac disease or
anti-phospholipids syndrome are excluded from the
study as they will all receive (or have received where it
concerns the retrospective patients) intensive surveil-
lance. The current study will not include women who
gave birth after 37 weeks gestational age.
The study population is recruited from six university
hospitals and seven large non-university tertiary referral
hospitals in the Netherlands: the Maastricht University
Medical Centre, University Medical Centre St. Radboud
Nijmegen, the Isala Clinics Zwolle, Erasmus Medical
Centre Rotterdam, Academic Medical Centre
Amsterdam, University Medical Centre Utrecht, Máxima
Medical Centre Veldhoven, the University Medical
Figure 1 Design of the study.
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Centre Groningen, Martini Hospital Groningen, Amphia
Hospital Breda, Atrium Medical Centre Heerlen, Jeroen
Bosch Hospital Den Bosch and Kennemer Hospital
Haarlem.
Recruitment procedures
For the prospective assessment, 50 care as usual patients
and 250 recurrence risk guided patients will be included
in the study.
The research nurse or the gynaecologist of participat-
ing hospitals identifies eligible women by screening the
appointment system of the outpatient clinic. After the
pregnant woman has given informed consent for partici-
pation in the study, patients in phase 1 will be enrolled
in care as usual whereas patients in phase 2 will be
enrolled in recurrence risk guided care.
In recurrence risk guided care (phase 2), a simple web
based risk calculator for the determination of recurrence
risk and required intensity of surveillance has been
developed and has been made accessible to gynaecolo-
gists and research nurses.
Information about the recommended components of
intensive monitoring and regular monitoring has been
provided together with the risk calculator.
For the retrospective assessment, 200 patients who
were treated according to care as usual will be used as a
comparator group based on matching. Matching criteria
will at least include maternal age (difference <5 years)
and gestational age at delivery. Consequently, at study
completion, there will be 250 care as usual patients who
will be compared with 250 recurrence risk guided
patients.
Data collection
For the prospective assessment (n = 50 care as usual;
n = 250 recurrence risk guided care), baseline demo-
graphics, past obstetric and medical history will be
recorded in case report forms. Information is obtained
on the condition of mother and child, infant weight,
infant length, morbidity and mortality from the infant
and maternal records. If applicable, details of the admit-
tance of the child to the neonatal intensive care, high
care or medium care unit will also be collected. All
activities in the hospital will be documented until three
months postpartum.
We will assess not only clinical outcomes, but also
health-related quality of life by using the EQ-5 D [19],
anxiety by using the STAI [20], depression by using the
Beck Depression Inventory [21] and posttraumatic stress
by using the PTSD Symptom Scale [22]. The QoL ques-
tionnaires will be administered at 3-month intervals
between baseline (before 20 weeks of pregnancy), at 29
weeks of pregnancy, ten days and three months postpar-
tum. Costs outside the hospital, such as GP care,
midwife and maternity care, productivity losses and out-
of-pocket expenses will be obtained by means of a retro-
spective cost questionnaire with a recall period of 3
months. Long-term follow up of the women and chil-
dren may be possible, but is not included in the current
study.
For women enrolled in the retrospective assessment
(n = 200), all data described above will be collected,
except data on health-related quality of life, anxiety,
depression, posttraumatic stress and costs outside the
hospital.
Monitoring protocols
Development of the protocols
All gynaecologists of the participating centres were
approached and they participated in a consensus pro-
cess, during which the final protocols were designed.
Nearly all were obstetricians specialised in hypertensive
disorders of pregnancy. After reaching consensus, the
protocols were distributed among all providers of care
in the study.
The protocols
Figure 2 shows the process of recurrence risk guided
care.
Regular monitoring
Women will visit the outpatient clinic 9 - 11 times: (8,
12), 16, 20, 24, 28, 32, 36, 38, 39 and 40 weeks gesta-
tional age. The visits at 16 and 20 weeks will be sched-
uled after the first trimester screening procedure and
the routine ultrasound screening for structural malfor-
mations, respectively. If feasible, six of these eleven visits
(12, 20, 28, 36, 39, 40) ought to be performed by the
same obstetrician, whereas the remaining five (reassur-
ing) visits (8, 16, 24, 32, 38) may be performed by a
nurse-practitioner or may be performed by the gynae-
cologist of the referring clinic (as of 32 weeks, in regular
and intensive monitoring).
Intensive monitoring
Women will visit the outpatient clinic 14 - 16 times: (8,
12), 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 39 and
40 weeks gestational age.
At two occasions during an intensive monitoring preg-
nancy (16 and 20 weeks), the patient will undergo a ser-
ies of diagnostic tests, which consist of
1. Measurements in urine: (micro)albuminuria, crea-
tinine, protein (protein serves to calculate the pro-
tein-to-creatinine ratio)
2. Measurements in blood: Haemoglobin, platelet
count, mean platelet volume, creatinine, urate, CRP,
glucose, fibronectin, Flt-1, endoglin
3. 24 h blood pressure monitoring. This assessment
is optional (not obligatory)
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4. Assessment of the Doppler flow velocity profile in
both uterine arteries (at 20 weeks)
Activities other than, or additional to those described
in the regular monitoring and intensive monitoring pro-
tocols (such as intercurrent admissions, additional out-
patient visits or diagnostic testing, or telephone/e-mail
contacts) will be registered.
Study outcomes
Recurrence risk guided care will be compared with care
as usual with respect to several outcomes.
Primary outcome is the occurrence of either early-
onset preeclampsia or HELLP syndrome. Early-onset
preeclampsia and early-onset HELLP syndrome are
defined according to the criteria of the International
Society for the Study of Hypertension in Pregnancy with
the criterion of delivery before 34 weeks after the last
menstrual period [23]. Secondary clinical outcome mea-
sures are: gestational age of onset of preeclampsia,
eclampsia, HELLP syndrome, intrauterine growth
restriction, caesarean section, admission to the neonatal
intensive care unit (NICU), gestational age at delivery
and maternal/infant mortality. Other secondary outcome
measures are societal costs, quality of life, anxiety,
depression, development of posttraumatic stress, satis-




Sample size calculation was based on the expected frac-
tion of women assigned to regular monitoring either on
the basis of the prediction rule or gestational age at the
time of previous delivery (67%), the expected failure rate
within this category (2%), a type I error (one-sided) of
0.05 and a type II error of 0.2. In order to be able to
exclude failure rates of 5% or more, 150 patients
assigned to regular monitoring are needed. This means
that results of about 225 patients in the recurrence risk
based care are needed. The estimated number of 250
allows for drop out and incomplete data of 25 patients.
Data analysis
The primary analysis concerns the incidence of recur-
rent early-onset preeclampsia or HELLP syndrome in
Figure 2 Recurrence risk guided care (phase 2).
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both groups (recurrence risk guided care versus care as
usual). Analyses will be adjusted for potential confoun-
ders (including demographic factors). Confidence inter-
vals will be adjusted by means of multilevel analysis
(hospital).
We will also analyse whether the new patient data
indicate the need for an update of the predictive model.
For this purpose, we will first compare the characteris-
tics of the original population used for model develop-
ment with the new population, the so-called “validation
population”. For example, the incidence of early-onset
preeclampsia may differ between the original and valida-
tion population. It is also possible that the latter popula-
tion has a different case-mix (i.e. differences in
distributions of the predictors in the population),
because, e.g., more hospitals are included. In addition,
different predictor-outcome associations and additional
predictors, that are not included in the model but are
either more or less frequent in the new population,
could play a role. We will also assess model perfor-
mance in the validation population by comparing sensi-
tivity, specificity, positive and negative predictive values
and discrimination and calibration compared to the per-
formance in the derivation population.
If the analysis should indicate lower accuracy than
expected, we will analyse to what extent all these factors
indeed affect the model’s accuracy and update the
model to obtain adequate accuracy. Updating of the
model will be done by means of re-calibration (step 1)
and model revision (step 2) [24-26].
Economic evaluation
A cost-effectiveness analysis will be performed from a
societal perspective, comparing the costs and effects of
recurrence risk guided care versus care as usual. The
time horizon of the study is 9 months (3 mo amenor-
rhea - 3 mo post partum). Discounting is not relevant
given the short time horizon.
The cost analysis will be performed according to the
Dutch guidelines for cost calculations [27]. All hospital
resource use and costs associated with care for pregnant
women and their newborns will be calculated from
study entry until 3 months post partum and include
costs such as outpatient visits and hospital admissions.
Cost prices will be obtained from participating hospitals.
If prices are not readily available, directive prices will be
used [27] or additional calculations will be made. Costs
in the analysis also include direct non-health care costs
(travel costs) and indirect costs (productivity loss).
Effect parameters are clinical outcomes, health related
quality of life, anxiety, depression and posttraumatic
stress.
Currently, no economic evaluation methods are avail-
able that integrate health outcomes of both mother and
child into a single outcome measure. However,
preeclampsia may have health effects for both the preg-
nant women and her (unborn) child. Therefore, the
main cost-effectiveness analysis will involve calculating
two incremental cost-effectiveness ratios (ICERs) expres-
sing 1) the cost per Quality Adjusted Life Year (QALY,
mother unit of analysis) and 2) the cost per live born
infant (child unit of analysis). To this end, a decision
model will be developed. Modelling in economic evalua-
tion is considered useful for example when experimental
observations from a trial are missing, which in this
study applies to some parameters in the care as usual
group [28,29].
Ethical considerations
This study has been approved by the ethical committee
of the University Hospital Maastricht (Ref.no. MEC 07-
2-078). A total of six academic and seven non-academic
hospitals participate in the study; all of them have com-
pleted their obligatory feasibility assessment procedure
successfully. Informed consent is being obtained from
all patients prior to enrolment into the study.
Discussion
This study is expected to yield information on health
outcomes and costs of adjusting the level of care to the
estimated probability of recurrent preeclampsia. The
results can provide a basis for more uniform (and evi-
dence-based) guidelines for care for formerly preeclamp-
tic women and possibly lead to more cost-effective
provision of health care. With respect to health care
costs, it is expected that mean costs per patient will
decrease as a result of a reduction in intensive maternal
and fetal surveillance. Potential savings can be even
higher, since the majority of women assigned to regular
monitoring may be adequately served by care provided
by in-hospital midwifes [30].
The close cooperation with many centres enables us
to reach a representative study population of pregnant
women who have experienced preeclampsia in their pre-
vious pregnancy, which enhances the applicability of the
results to all former preeclamptic women. Results of this
study will be disseminated by means of presentations at
scientific meetings and peer-reviewed publications.
Study outcomes will also be communicated directly to
the NVOG (Dutch Association of Obstetrics and Gynae-
cology), KNOV (Royal Dutch Association of Midwives),
and the Dutch HELLP syndrome foundation. In addi-
tion, we will cooperate with the NVOG in order to pro-
duce recommendations for the formulation of
guidelines. The recommendations could either be inte-
grated into the current guideline on Hypertensive Disor-
ders in Pregnancy, or be used to develop a new
guideline. The results of this study will be used to stan-
dardise the postpartum evaluation of women with a
recent history of preeclampsia or HELLP syndrome. It is
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expected that the number of tests in the postpartum
evaluation will not only be reduced, but also
synchronised.
A randomised controlled trial design is usually pre-
ferred over any other design. However, for this study
such a design was not considered applicable. A before-
after study was chosen (instead of a fully prospective,
randomised study) because of the risk of care as usual
being contaminated with the regular monitoring and
intensive monitoring protocols. Because current care as
usual is not standardised, and blinding of the participat-
ing gynaecologists with respect to predictive factors for
recurrent disease is practically unfeasible, a randomised
design could reduce the contrast between study arms
and thereby threaten the validity of the results.
As the care provided to women assigned to regular
monitoring is less intense, a possible consequence may
be that the detection of clinical signs of preeclampsia or
HELLP syndrome is somewhat later than in the current
care as usual approach. However, we do not expect this
to lead to adverse maternal or fetal outcomes, because
the prediction model suggests that the recurrence rate
in this group is low (<1%) whereas there is also
increased alertness for early signs of pregnancy compli-
cations in women with a history of preeclampsia or
HELLP syndrome.
In summary, the PreCare study is designed to provide
information on whether recurrence risk guided care is a
worthwhile strategy compared to current care for preg-
nant women who suffered from preeclampsia or HELLP
syndrome during their previous pregnancy.
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